# | Title | Journal | Year | Citations |
---|
1 | Ferroptosis, a new form of cell death: opportunities and challenges in cancer | Journal of Hematology and Oncology | 2019 | 924 |
2 | Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications | Journal of Hematology and Oncology | 2019 | 866 |
3 | The biology and role of CD44 in cancer progression: therapeutic implications | Journal of Hematology and Oncology | 2018 | 802 |
4 | Ferroptosis, necroptosis, and pyroptosis in anticancer immunity | Journal of Hematology and Oncology | 2020 | 698 |
5 | The effects of β-glucan on human immune and cancer cells | Journal of Hematology and Oncology | 2009 | 649 |
6 | Targeting the Wnt/β-catenin signaling pathway in cancer | Journal of Hematology and Oncology | 2020 | 625 |
7 | Exosomes in cancer: small particle, big player | Journal of Hematology and Oncology | 2015 | 611 |
8 | Tumor-associated macrophages: from basic research to clinical application | Journal of Hematology and Oncology | 2017 | 607 |
9 | Next generation of immune checkpoint therapy in cancer: new developments and challenges | Journal of Hematology and Oncology | 2018 | 597 |
10 | Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers | Journal of Hematology and Oncology | 2013 | 594 |
11 | Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy | Journal of Hematology and Oncology | 2019 | 555 |
12 | Targeting mTOR for cancer therapy | Journal of Hematology and Oncology | 2019 | 542 |
13 | Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma | Journal of Hematology and Oncology | 2015 | 537 |
14 | SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19 | Journal of Hematology and Oncology | 2020 | 505 |
15 | Immune checkpoint inhibitors of PD-L1 as cancer therapeutics | Journal of Hematology and Oncology | 2019 | 485 |
16 | Nanomaterials for cancer therapy: current progress and perspectives | Journal of Hematology and Oncology | 2021 | 456 |
17 | Wnt/beta-catenin pathway: modulating anticancer immune response | Journal of Hematology and Oncology | 2017 | 448 |
18 | EZH2: a novel target for cancer treatment | Journal of Hematology and Oncology | 2020 | 447 |
19 | Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy | Journal of Hematology and Oncology | 2019 | 416 |
20 | Clinical applications of mesenchymal stem cells | Journal of Hematology and Oncology | 2012 | 400 |
21 | A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma | Journal of Hematology and Oncology | 2018 | 388 |
22 | Long non-coding RNA: a new player in cancer | Journal of Hematology and Oncology | 2013 | 382 |
23 | Mechanism of action of lenalidomide in hematological malignancies | Journal of Hematology and Oncology | 2009 | 373 |
24 | Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents | Journal of Hematology and Oncology | 2010 | 373 |
25 | Role of platelets and platelet receptors in cancer metastasis | Journal of Hematology and Oncology | 2018 | 370 |
26 | The interplay between m6A RNA methylation and noncoding RNA in cancer | Journal of Hematology and Oncology | 2019 | 367 |
27 | Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer | Journal of Hematology and Oncology | 2020 | 359 |
28 | Functions of lncRNA HOTAIR in lung cancer | Journal of Hematology and Oncology | 2014 | 351 |
29 | An evolving new paradigm: endothelial cells – conditional innate immune cells | Journal of Hematology and Oncology | 2013 | 350 |
30 | Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development | Journal of Hematology and Oncology | 2018 | 333 |
31 | Nanotechnology in cancer diagnosis: progress, challenges and opportunities | Journal of Hematology and Oncology | 2019 | 314 |
32 | NK cell-based cancer immunotherapy: from basic biology to clinical development | Journal of Hematology and Oncology | 2021 | 312 |
33 | Diverse functions of miR-125 family in different cell contexts | Journal of Hematology and Oncology | 2013 | 304 |
34 | Abscopal effect of radiotherapy combined with immune checkpoint inhibitors | Journal of Hematology and Oncology | 2018 | 303 |
35 | Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors | Journal of Hematology and Oncology | 2016 | 302 |
36 | Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial | Journal of Hematology and Oncology | 2017 | 302 |
37 | Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel | Journal of Hematology and Oncology | 2018 | 302 |
38 | A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer | Journal of Hematology and Oncology | 2013 | 301 |
39 | Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy | Journal of Hematology and Oncology | 2019 | 296 |
40 | Next generation of immune checkpoint inhibitors and beyond | Journal of Hematology and Oncology | 2021 | 293 |
41 | Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 protein | Journal of Hematology and Oncology | 2017 | 291 |
42 | CircRNAs in cancer metabolism: a review | Journal of Hematology and Oncology | 2019 | 288 |
43 | New development in CAR-T cell therapy | Journal of Hematology and Oncology | 2017 | 282 |
44 | The role of stromal cancer-associated fibroblasts in pancreatic cancer | Journal of Hematology and Oncology | 2017 | 281 |
45 | Regulation of PD-L1 expression in the tumor microenvironment | Journal of Hematology and Oncology | 2021 | 281 |
46 | Targeting the IDO1 pathway in cancer: from bench to bedside | Journal of Hematology and Oncology | 2018 | 277 |
47 | M6A-mediated upregulation of LINC00958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinoma | Journal of Hematology and Oncology | 2020 | 277 |
48 | Emerging therapies for small cell lung cancer | Journal of Hematology and Oncology | 2019 | 273 |
49 | Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy | Journal of Hematology and Oncology | 2016 | 271 |
50 | Roles of METTL3 in cancer: mechanisms and therapeutic targeting | Journal of Hematology and Oncology | 2020 | 269 |